

Diana Tran

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9642723/publications.pdf>

Version: 2024-02-01

9
papers

54
citations

1937685
4
h-index

1720034
7
g-index

9
all docs

9
docs citations

9
times ranked

64
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical and Economic Benefits of Antimicrobial Stewardship Programs in Hemodialysis Facilities. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1389-1397.	4.5	18
2	Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 529-538.	4.0	12
3	Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model. <i>Lung Cancer</i> , 2020, 139, 185-194.	2.0	11
4	Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy. <i>PharmacoEconomics - Open</i> , 2021, , 1.	1.8	5
5	The impact of clinical heterogeneity on conducting network meta-analyses in transthyretin amyloidosis with polyneuropathy. <i>Current Medical Research and Opinion</i> , 2020, 36, 799-808.	1.9	4
6	Estimating the annual economic burden for the management of patients with transthyretin amyloid polyneuropathy in Spain. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 967-973.	1.4	2
7	Impact of Tafamidis on Life Expectancy and Quality of Life of Transthyretin Amyloid Cardiomyopathy Patients. <i>Journal of Cardiac Failure</i> , 2020, 26, S132-S133.	1.7	1
8	Systematic literature review of evidence in amyloid light-chain amyloidosis. <i>Journal of Comparative Effectiveness Research</i> , 2022, 11, 451-472.	1.4	1
9	A reply to "Correspondence Re: Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model". <i>Lung Cancer</i> , 2021, 151, 110-111.	2.0	0